Nurix Therapeutics IncNASDAQ:NRIX
- LAST PRICE15.5100
- TODAY'S CHANGE (%)-0.3900 (-2.4528%)
- Bid / Lots15.4900/ 4
- Ask / Lots15.5200/ 4
- Open / Previous Close15.8700 / 15.9000
- Day Range
- 52 Week Range
- Volume121,371
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRIX |
|---|---|---|
| 09:32 ET | 6402 | 15.825 |
| 09:34 ET | 1846 | 15.8 |
| 09:36 ET | 100 | 15.825 |
| 09:38 ET | 100 | 15.77 |
| 09:41 ET | 1142 | 15.615 |
| 09:43 ET | 955 | 15.5 |
| 09:45 ET | 100 | 15.565 |
| 09:52 ET | 1600 | 15.43 |
| 09:54 ET | 400 | 15.53 |
| 09:56 ET | 200 | 15.5 |
| 09:57 ET | 100 | 15.59 |
| 10:01 ET | 400 | 15.56 |
| 10:03 ET | 400 | 15.55 |
| 10:06 ET | 500 | 15.51 |
| 10:08 ET | 587 | 15.4 |
| 10:10 ET | 100 | 15.39 |
| 10:12 ET | 300 | 15.405 |
| 10:17 ET | 508 | 15.495 |
| 10:19 ET | 46856 | 15.4 |
| 10:21 ET | 2375 | 15.46 |
| 10:24 ET | 439 | 15.46 |
| 10:26 ET | 400 | 15.43 |
| 10:28 ET | 500 | 15.52 |
| 10:30 ET | 507 | 15.565 |
| 10:33 ET | 1620 | 15.55 |
| 10:35 ET | 614 | 15.58 |
| 10:37 ET | 100 | 15.55 |
| 10:39 ET | 4060 | 15.54 |
| 10:42 ET | 1311 | 15.47 |
| 10:46 ET | 1100 | 15.43 |
| 10:50 ET | 582 | 15.385 |
| 10:51 ET | 359 | 15.425 |
| 10:57 ET | 1016 | 15.37 |
| 11:02 ET | 1703 | 15.28 |
| 11:04 ET | 100 | 15.29 |
| 11:06 ET | 304 | 15.295 |
| 11:08 ET | 100 | 15.32 |
| 11:09 ET | 656 | 15.355 |
| 11:11 ET | 200 | 15.38 |
| 11:13 ET | 100 | 15.381 |
| 11:18 ET | 1077 | 15.38 |
| 11:22 ET | 256 | 15.405 |
| 11:24 ET | 5746 | 15.47 |
| 11:26 ET | 200 | 15.475 |
| 11:27 ET | 1040 | 15.5 |
| 11:29 ET | 1049 | 15.46 |
| 11:31 ET | 800 | 15.5 |
| 11:33 ET | 100 | 15.52 |
| 11:36 ET | 100 | 15.55 |
| 11:38 ET | 558 | 15.54 |
| 11:40 ET | 300 | 15.51 |
Yesterday
DJ Nurix Therapeutics Is Maintained at Buy by Stifel, from 8:00AM ET on Wednesday May 15, 2024 by Dow Jones
8:00AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
DJ Nurix Therapeutics Price Target Maintained With a $31.00/Share by Needham, from 12:15PM ET on Tuesday May 14, 2024 by Dow Jones
12:15PM ET on Tuesday May 14, 2024 by Dow JonesNurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024), from 10:00AM ET on Tuesday May 14, 2024 by Dow Jones
10:00AM ET on Tuesday May 14, 2024 by Dow JonesDJ Nurix Therapeutics Initiated at Overweight by Stephens & Co., from 6:13AM ET on Tuesday May 14, 2024 by Dow Jones
6:13AM ET on Tuesday May 14, 2024 by Dow Jones
May 7, 2024
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference, from 7:00AM ET on Tuesday May 07, 2024 by Dow Jones
7:00AM ET on Tuesday May 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nurix Therapeutics Inc | 942.9M | -5.9x | --- |
Regenxbio Inc | 796.0M | -2.7x | --- |
Arcutis Biotherapeutics Inc | 1.1B | -2.3x | --- |
CureVac NV | 715.5M | -2.7x | --- |
SAGE Therapeutics Inc | 704.7M | -1.4x | --- |
Zymeworks Inc | 646.9M | -5.2x | --- |
Company Information
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Contact Information
- Headquarters
- 1700 Owens St Ste 205SAN FRANCISCO, CA, United States 94158-0006
- Phone
- 415-660-5320
- Fax
- 415-525-4200
Executives
- Independent Chairman of the Board
- David Lacey
- President, Chief Executive Officer, Director
- Arthur Sands
- Chief Financial Officer
- Hans van Houte
- Chief Scientific Officer
- Gwenn Hansen
- Chief Legal Officer, Chief Compliance Officer, Secretary
- Christine Ring
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $942.9M |
|---|---|
Revenue (TTM) | $80.9M |
Shares Outstanding | 59.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.18 |
EPS | $-2.65 |
Book Value | $4.12 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | 11.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -194.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
